The request must be processed and approved by Michael Dyer, PhD; Dr. Alberto Pappo, MD; and the Childhood Solid Tumor Network (CSTN) committee. After approval, a Material Transfer Agreement (MTA) will be sent to your institution for signature and execution. If there is a need for further clarification prior to approval, we will contact you directly.
The typical process is as follows:
- Request is submitted
- CSTN approves request
- CSTN sends MTA to requesting institution
- Requesting institution signs MTA, sends to CSTN for signature
- CSTN confirms shipping details and ships samples
- Request is closed
Our goal is to share samples for timely use in order to drive more rapid discovery in the field, while minimizing the risk that valuable samples may be “stockpiled” for possible future use. We also prefer to keep numbers small to reduce the risk of loss or damage incurred by shipping large numbers of cryovials.
The timeline depends on your institution and on the time required to get the MTA signed and executed. Once the MTA is signed, we will contact you within a week and confirm shipment details.
The consent form under which the patient tumor samples were collected stipulates that all samples be de-identified and sent out under an MTA.
No. The CSTN actively tracks samples that have been distributed so that we may contact investigators should updated information about the sample become available. Please encourage any interested research colleagues to contact us directly by filling out a request form, and we will be happy to assist.
Stewart E*, Federico SM*, Chen X*, Shelat AA, Bradley C, Gordon B, Karlstrom A, Twarog NR, Clay MR, Bahrami A, Freeman BB 3rd, Xu B, Zhou X, Wu J, Honnell V, Ocarz M, Blankenship K, Dapper J, Mardis ER, Wilson RK, Downing J, Zhang J, Easton J, Pappo A, Dyer MA, Orthotopic patient-derived xenografts of paediatric solid tumours, Nature. 2017 Sep 7;549(7670):96-100
No. We have been focused on propagating the xenografts and banking them down for sharing. In the future we may create cell lines from these samples.
You will receive the sample, media conditions and SOPs for implantation, freezing and thawing. You will also receive a sheet with specific information about the tumor sample (phenotype, gene information, etc.).
You can subscribe to our newsletter to receive regular updates on new resources, data and advances emerging from the CSTN. We also share information about relevant clinical trials.